A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy

PRIMARY OBJECTIVES: I. To determine if maintenance therapy with nivolumab can decrease the incidence of colon adenomas in a population of patients with genetic predisposition to colorectal cancer and a history of hemicolectomy due to colon cancer or advanced colon adenoma. SECONDARY OBJECTIVES: I. T...

Full description

Bibliographic Details
Other Involved Persons: Joanne Jeter
Format: eBook
Language:English
Published: Bethesda (Maryland) : ClinicalTrials.gov August 8, 2019
Item Description:Copyright: Source: ClinicalTrials.gov (no modifications made)
Copyright: ClinicalTrials.gov processed this data on December 13, 2019
Copyright: Last update posted on ClinicalTrials.gov: August 8, 2019
Copyright: Last updated: 2019-12-16
Physical Description:Online-Ressource
Subjects:
QR Code: Show QR Code
LEADER 03050nmm a2200541 c 4500
001 CTG002811995
003 DE-601
005 20191218043849.0
007 cr uuu---uuuuu
008 181201s2019 o 000 0 eng d
024 8 |a OSU-17198 
024 8 |a NCI-2018-01491 
024 8 |a P30CA016058 
024 8 |a NCT03631641 
028 5 2 |a CTg_2019-12-16.pp 
035 |a (DE-599)NCTNCT03631641 
040 |b ger  |c GBVCP  |e rda 
041 0 |a eng 
084 |a pha  |q DE-601  |2 z 
245 0 0 |a A Phase II Study of PD-1 Inhibition for the Prevention of Colon Adenomas in Patients With Lynch Syndrome and a History of Partial Colectomy  |h Elektronische Ressource 
264 3 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c August 8, 2019 
300 |a Online-Ressource 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Copyright: Source: ClinicalTrials.gov (no modifications made) 
500 |a Copyright: ClinicalTrials.gov processed this data on December 13, 2019 
500 |a Copyright: Last update posted on ClinicalTrials.gov: August 8, 2019 
500 |a Copyright: Last updated: 2019-12-16 
510 3 |a Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy 
520 |a PRIMARY OBJECTIVES: I. To determine if maintenance therapy with nivolumab can decrease the incidence of colon adenomas in a population of patients with genetic predisposition to colorectal cancer and a history of hemicolectomy due to colon cancer or advanced colon adenoma. SECONDARY OBJECTIVES: I. To assess the safety of nivolumab maintenance therapy in this population. II. To obtain preliminary data on the short-term incidence of advanced colon adenomas (measuring greater than 10 mm or with high-grade dysplasia) and colon and non-colonic cancers in Lynch patients treated with maintenance nivolumab. EXPLORATORY OBJECTIVES: I. To determine biomarkers of immunologic activity associated with biologic activity of nivolumab in this population. OUTLINE: Participants receive nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 3 months, every 6 months for 1 year, then every 12 weeks thereafter. 
653 2 |a Clinical Study 
653 2 |a Clinical Trial, Phase II 
653 2 |a Adenoma 
653 2 |a Colorectal Neoplasms, Hereditary Nonpolyposis 
653 2 |a Syndrome 
653 4 |a Clinical Study Status: Suspended 
653 4 |a Colon Adenoma 
653 4 |a Colon Carcinoma 
653 4 |a Lynch Syndrome 
653 4 |a MLH1 Gene Mutation 
653 4 |a MSH2 Gene Mutation 
653 4 |a Klinische Studie 
655 0 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a Joanne Jeter  |e Herausgebendes Organ  |4 isb 
856 4 1 |u https://clinicaltrials.gov/show/NCT03631641  |z LF  |3 Volltext 
912 |a GBV_CTG 
951 |a BO